Medical Treatment of Neuroendocrine Gut and Pancreatic Tumors

Reference

• Berge T, Linell F. Carcinoid tumors. Acta Pathol Microbiol Immunol Scand (A) 1976; 84: 322
   Google Scholar
• Norheim I, öberg K, Theodorsson-Norheim E, et al. Malignant carcinoid tumors; An analysis of 103 patients with regard to tumor localization, hormone production and survival. Ann Surg 1987; 206: 115
   PubMed Web of Science ®Google Scholar
• Eriksson B. Recent advances in the diagnosis and management of endocrine pancreatic tumors (Thesis). Acta Universitatis Upsaliensis 1988; 160
   Google Scholar
• Murray-Lyon I M, Eddlestone A LWF, Williams R, et al. Treatment of multiple hormone producing islet cell tumour with streptozotocin. Lancet 1968; 2: 895
   PubMed Web of Science ®Google Scholar
• Broder L E, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79: 108
   PubMed Web of Science ®Google Scholar
• Moertel C G, Hanley J A, Johnsson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980; 303: 1189
   PubMed Web of Science ®Google Scholar
• öberg K, Boström H, Johansson H. Treatment of malignant endocrine gastrointestinal tumours. Results from an Uppsala material. Ups J Med Sci 1984; 39: 179, Suppl
   Google Scholar
• Moertel CG. Treatment of advanced and metastatic gastrointestinal endocrine tumors, the carcinoid tumor and islet cell carcinoma. Ups J Med Sci 1984; 39: 159, Suppl
   Google Scholar
• Kessinger A, Foley J F, Lemon HM. DTIC therapy for malignant islet cell tumors. Proc Am Soc Clin Oncol 1982; 1: 169
   Google Scholar
• Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1: 727
   PubMed Web of Science ®Google Scholar
• van Hazel G A, Rubin J, Moertel CG. Treatment of metastatic carcinoid tumor with dactinomycin or dabarbazine. Cancer Treat Rep 1983; 67: 583
   PubMedGoogle Scholar
• Moertel C G, Rubin J, O'Connell MJ. A phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat Rep 1986; 70: 1459
   PubMedGoogle Scholar
• Schein P S, O'Connell M J, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin. Cancer 1974; 34: 993
   PubMed Web of Science ®Google Scholar
• Moertel C G, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2: 327
   PubMedGoogle Scholar
• öberg K, Norheim I, Lundqvist G, Wide L. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin—alone or in combination with 5-FU. Acta Oncol 1987; 26: 429
   PubMed Web of Science ®Google Scholar
• Kelsen D P, Cheng E, Kemeny N, Magill G B, Yagoda A. Streptozotocin and Adriamycin in the treatment of APUD tumors (carcinoid, islet cell and medullary carcinomas of the thyroid). Proc Am Assoc Cancer Res 1982; 23: 433
   Google Scholar
• Bukowski R M, Stephens R, Oishi N, Petersen R, Chen T. Phase II trial of 5-FU, Adriamycin, cyclophosphamide and streptozotocin (FAC-S) in metastatic carcinoid. Proc Am Soc Clin Oncol 1983; 2: 130
   Google Scholar
• Pless J, Bauer W, Briner U, et al. Chemistry and pharmacology of SMS 201–995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol 1986; 21: 54
   Web of Science ®Google Scholar
• Eriksson B, öberg K, Andersson T, et al. Treatment of malignant endocrine pancreatic tumours with a new long-acting somatostatin analogue SMS 201–995. Scand J Gastroenterol 1988; 23: 508
   PubMed Web of Science ®Google Scholar
• öberg K, Norheim I, Lundqvist G, Wide L. Treatment of the carcinoid syndrome with SMS 201–995, a somatostatin analogue. Scand J Gastroenterol 1986; 21: 191
   Web of Science ®Google Scholar
• Kvols L K, Moertel C G, O'Connell M S, et al. Treatment of the malignant carcinoid syndrome; Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663
   PubMed Web of Science ®Google Scholar
• öberg K, Funa K, Alm G. Effects of leukocyte interferon upon clinical symptoms and hormone levels in patients with midgut carcinoid tumors and the carcinoid syndrome. N Engl J Med 1983; 309: 129
   PubMed Web of Science ®Google Scholar
• öberg K, Lindström H, Aim G, Lundqvist G. Successful treatment of therapy-resistant pancreatic cholera with human leukocyte interferon. Lancet 1985; 1: 725
   PubMed Web of Science ®Google Scholar
• Eriksson B, öberg K, Aim G, et al. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet 1986; 2: 1307
   PubMed Web of Science ®Google Scholar
• öberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon. Long-term results. Cancer Treat Rep 1986; 70: 1297
   PubMedGoogle Scholar
• Smith D B, Scarffe J H, Wagstraff J, Johnston RJ. Phase II trial of rDNA alpha 2b interferon in patients with malignant carcinoid tumors. Cancer Treat Rep 1987; 71: 1265
   PubMedGoogle Scholar
• Doberauer C, Niederle N, Kloke O, et al. Behandlung des metastasierten Karzinoides mit rekombinantem Interferon alfa 2b. Onkologie 1987; 10: 340
   PubMedGoogle Scholar
• Hansen L E, Schrumpf E, Kolbenstvedt, et al. Recombinant human alpha2-interferon in the treatment of malignant metastatic mid-gut carcinoid tumours. J Interferon Res 1987; 7: 735
   Google Scholar
• Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1503
   Web of Science ®Google Scholar
• Funa K, Gazdar A F, Doyle A, et al. In vivo induction of β2 microglobulin after interferon therapy on small-cell lung cancer and mid-gut carcinoid patients. Clin Immunol Immunopathol 1986; 41: 159
   PubMedGoogle Scholar
• Moertel C G, Sauer W G, Dockerty M B, et al. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901
   PubMed Web of Science ®Google Scholar
• Zeitels J, Naunheim K, Kaplan E L, Strauss II F. Carcinoid tumors; A 37 years experience. Arch Surg 1982; 117: 732
   PubMedGoogle Scholar